Hemadsorption to Enhance Drug Elimination in Intoxications
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 18
- Locations
- 1
- Primary Endpoint
- Difference in time to upper limit of normal of the dosed drug with versus without hemadsorption
Study Overview
Brief Summary
In this trial the investigators assess the effectiveness of applying a hemadsorber (cytosorb®) in removing benzodiazepines or tricyclic antidepressants in intoxicated patients admitted to ICU with prolonged impaired consciousness. This is a one arm interventional investigation where a hemadsorption filter is applied in patients fulfilling inclusion criteria 8 hours after admission. Plasma titer of the neurodepressing drug will be collected sequentially both before and after start of hemadsorption to evaluate the speed of drug elimination before and after application of a hemadsorption filter. Pre- and post filter titers will be obtained to evaluate adsorbability and to evaluate time to saturation of the filter.
Detailed Description
In this prospective interventional study with medical device, the investigotors would include 18 patients admitted to ICU after an intoxication with a quantifiable neurodepressing drugs (type benzodiazepines or tricyclic antidepressants) and with impaired consciousness defined as need for intubation or need for Flumazenil to prevent intubation. Naloxone is administered per standard of care to identify if opioid intoxications is the main reason of neurodepression. Patients requiring mechanical ventilation for other reasons than impaired consciousness due to this intoxication or indication for prolonged use of sedatives are excluded.
Patients with at least one risk factor for delayed drug elimination (Chronic kidney disease G3b or CHILD-Pugh B or C) and persisting impaired consciousness after eight hours (including patients with persisting need for flumazenil) and having 5 plasma titers of the neurodepressing drug with intervals of 2 hours will be initiated on a hemadsorption filter after contact between the treating team and either dr. Michaël Mekeirele or dr. Tim Balthazar to verify inclusion criteria. Patients fulfilling inclusion criteria but lacking the 5 plasma titers will get additional plasma titers with intervals of 2 hours until 5 plasma titers are obtained. If these patients still fulfill inclusion criteria at that time then a hemadosorption filter will be initiated.
After starting hemadsorption a plasma titer pre- and post filter will be obtained after 15 minutes and every 4 hours after starting hemadsorption for the first 24 hours. After this timepoint additional plasma titers will be obtained every 24 hours until stopping hemadsorption or normalisation of the plasma titer.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •older than18 years
- •Admission to ICU
- •GCS < 8 or requiring Flumazenil 8 hours after hospital admission
- •Having an intoxication with a benzodiazepine or tricyclic antidepressant that we can measure/quantify
- •Having a risk factor for delayed drug elimination defined as either Cirrhosis CHILD B/C or chronic kidney insufficiency KDIGO 3b or worse
Exclusion Criteria
- •Pregnant patient
- •Patients in chronic dialysis before admission
- •Need for mechanical ventilation for other reasons than intoxications (e.g. pneumonia, neurotrauma)
- •Concomitant pathology requiring continued intravenous sedation
- •Known history of seizures
- •Contra-indication to heparin use
- •DNR restricting the use of mechanical ventilation or dialysis
Arms & Interventions
Hemadsorption
Hemadsorption via a dialysis catheter will be performed in patients who are unconscious due to an intoxication with quantifiable benzodiazepines or tricyclic antidepressants 8 hours after admission. Before and after application fo this hemadsorption filter plasma titers of this drug will be obtained. After application of the hemadsorption filter pre- and post-filter titers will be obtained.
Intervention: Hemadsorption filter (Device)
Outcomes
Primary Outcomes
Difference in time to upper limit of normal of the dosed drug with versus without hemadsorption
Time Frame: From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days
Based on plasma titers before start of hemadsorption the half life of the drug can be calculated. A theoretical intersection with the upper boundary of normal of the intoxicated drug plasma titer can be calculated. This will be statistically compared to the real time of attaining this titer after start of hemadsorption.
Secondary Outcomes
- Bleeding during hemadsorption therapy(From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days)
- Adsorbability of the individual neurodepressing drugs(From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days)
- Time to saturation of hemadsorption filter(From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days)
- Catheter related complications(From enrollment to the removal of the dialysis catheter +/- 3 days)
- Cost effectiveness of applying a Cytosorb® hemadsorption filter(From enrollment to discharge from ICU (+/- 1 week))
- Duration mechanical ventilation(From enrollment to extubation (+/- 3 days))
- Duration ICU stay(From enrollment to discharge from ICU (+/- 1 week))
- Need and duration vasopressors(From enrollment to stop of vasopressors (+/- 3 days))
- Seizures during hemadsorption therapy(From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days)
Investigators
Michaël Mekeirele
Medical Doctor, Principal Investigator
Universitair Ziekenhuis Brussel